Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.35 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11122429 | 0.97 | ALDH1A1 (0.44) | MAPTALDH1A1MAPK1TRIM24TRIM33 | |
| SCHEMBL1073890 | 0.97 | ALDH1A1 (0.44) | MAPTALDH1A1MAPK1TRIM24TRIM33 | |
| SCHEMBL7014418 | 0.97 | ALDH1A1 (0.44) | MAPTALDH1A1MAPK1TRIM24TRIM33 | |
| SCHEMBL8348766 | 0.97 | ALDH1A1 (0.44) | MAPTALDH1A1MAPK1TRIM24TRIM33 | |
| SCHEMBL427737 | 0.91 | ALDH1A1 (0.47) | MAPTALDH1A1MAPK1TRIM24TRIM33 | |
| SCHEMBL8348928 | 0.90 | — | — | |
| SCHEMBL7999538 | 0.90 | — | — | |
| SCHEMBL8348774 | 0.90 | — | — | |
| SCHEMBL427801 | 0.88 | ALDH1A1 (0.50) | MAPTALDH1A1MAPK1TRIM24TRIM33 | |
| SCHEMBL11330896 | 0.86 | TRIM24 (0.50) | MAPTALDH1A1MAPK1TRIM24TRIM33 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3107916-B1 | SPIRO-OXAZOLONES | HOFFMANN LA ROCHE (CH) | 2019-03-20 | — | — | EP | disclosed |
| US-9828385-B2 | Spiro-oxazolones | HOFFMANN-LA ROCHE INC. (US) | 2017-11-28 | — | — | US | disclosed |
| EP-3107916-A1 | SPIRO-OXAZOLONES | F. Hoffmann-La Roche AG (CH) | 2016-12-28 | — | — | EP | disclosed |
| US-20160355522-A1 | SPIRO-OXAZOLONES | HOFFMANN-LA ROCHE INC. (US) | 2016-12-08 | — | — | US | disclosed |
| WO-2015124541-A1 | SPIRO-OXAZOLONES | F. HOFFMANN-LA ROCHE AG (CH) | 2015-08-27 | — | — | WO | disclosed |
| EP-0963987-B1 | Spiro(piperidine-4,1'-pyrrolo(3,4-c)pyrrole) | HOFFMANN LA ROCHE (CH) | 2002-08-28 | — | — | EP | disclosed |
| EP-0921125-B1 | 1,3,8-Triazaspiro[4,5]decan-4-on derivatives | HOFFMANN LA ROCHE (CH) | 2002-01-30 | — | — | EP | disclosed |
| EP-0970957-B1 | Diaza-spiro[3,5] nonane derivatives | HOFFMANN LA ROCHE (CH) | 2001-08-16 | — | — | EP | disclosed |
| US-6113527-A | 3,3-BIS-HYDROXYMETHYL-7-(CIS-4-ISOPROPYL-CYCLOHEXYL)-1-PHENYL -1,7-DIAZA-SPIRO-(3.5)NONANE-2-ONE, FOR EXAMPLE; AGONISTS OF THE ORPHANIN FQ (OFQ) RECEPTOR; USEFUL IN THE TREATMENT OF PSYCHIATRIC, NEUROLOGICAL AND PHYSIOLOGICAL DISORDERS | HOFFMANN-LA ROCHE INC. (US) | 2000-09-05 | — | — | US | disclosed |
| US-6075034-A | Spiro[piperidine-4,1'-pyrrolo [3,4-C] pyrrole]derivatives | HOFFMANN-LA ROCHE INC. (US) | 2000-06-13 | — | — | US | disclosed |
| US-6043366-A | USEFUL IN TREATING DISORDERS INVOLVING THE ORPHANIN FQ(A SEVENTEEN AMINO ACID LONG PEPTIDE) RECEPTOR. | HOFFMAN-LA ROCHE INC. (US) | 2000-03-28 | — | — | US | disclosed |
| EP-0970957-A1 | Diaza-spiro[3,5] nonane derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2000-01-12 | — | — | EP | disclosed |
| EP-0963987-A2 | Spiro(piperidine-4,1'-pyrrolo(3,4-c)pyrrole) | F. HOFFMANN-LA ROCHE AG (CH) | 1999-12-15 | — | — | EP | disclosed |
| EP-0921125-A1 | 1,3,8-Triaza-spiro 4,5 decan-4-on derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1999-06-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160355522-A1 | SPIRO-OXAZOLONES | AVPR1A, AVPR1B, AVPR2 | MAPT 2314/4885ALDH1A1 1228/4885MAPK1 3020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.